Implantable device for increasing tear production

Information

  • Patent Grant
  • 10610695
  • Patent Number
    10,610,695
  • Date Filed
    Friday, September 8, 2017
    7 years ago
  • Date Issued
    Tuesday, April 7, 2020
    4 years ago
Abstract
Described here are devices, systems, and methods for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. In some variations, the devices may be in the form of a contact lens. The contact lens may comprise a lens body and a stimulator chip, where the stimulator chip is embedded in the lens body. An external power source wirelessly transmits energy to the stimulator chip, where the stimulator chip may convert the energy to an electric waveform to stimulate the cornea, conjunctiva, and/or subconjunctiva. Stimulation may activate the lacrimal reflex to increase tear production. The devices and systems for increasing tear production may be used in methods of treating dry eye, reducing the symptoms of tired eye, increasing comfort for contact lens wearers, and extending the number of years a contact lens user can wear contacts. Also described are methods of manufacturing a contact lens.
Description
FIELD

The present disclosure relates generally to stimulation devices, systems, and methods of use thereof. The stimulation systems may be used to stimulate the cornea and/or conjunctiva and/or subconjunctiva of the eye to increase tear production in the treatment of one or more indications, such as dry eye.


BACKGROUND

Dry eye is a condition that affects millions of people. More than 40 million people in North America have some form of dry eye, and many millions more suffer worldwide. Dry eye results from the disruption of the natural tear film on the surface of the eye, and can result in ocular discomfort, visual disturbance and a reduction in vision-related quality of life. Activities of daily living such as driving, computer use, housework, and reading have also been shown to be negatively impacted by dry eye. Patients with severe cases of dry eye are at risk for serious ocular health deficiencies such as corneal ulceration, and can experience a quality of life deficiency comparable to that of moderate-severe angina.


Dry Eye Disease (“DED”) is a clinical condition of the eye. DED is progressive in nature, and fundamentally results from insufficient tear coverage on the surface of the eye. This poor tear coverage prevents healthy gas exchange and nutrient transport for the ocular surface, promotes cellular desiccation, and creates a poor refractive surface for vision. Poor tear coverage typically results from: 1) insufficient aqueous tear production from the lacrimal glands (e.g. secondary to post-menopausal hormonal deficiency, autoimmune disease, LASIK surgery, etc.), and/or 2) excessive evaporation of aqueous tear resulting from dysfunction of the meibomian glands. Low tear volume causes a hyperosmolar environment that induces an inflamed state of the ocular surface. This inflammatory response induces apoptosis of the surface cells, which in turn prevents proper distribution of the tear film on the ocular surface so that any given tear volume is rendered less effective. This initiates a vicious cycle where more inflammation can ensue, causing more surface cell damage, etc.


External factors that are not clinically based may also contribute to dry eye. These factors can include medications, dehydration, and environmental pollutants. Contact lenses, particularly soft contact lenses, are also known to cause or exacerbate the symptoms of dry eye. The contact lenses continually absorb water from the surface of the tear film in order to keep hydrated, leading to dryness of the eye. Dry eye can also be a symptom of the condition commonly known as “tired eye.” During extended periods of focused, intense use, such as heavy computer use and long distance driving, the eyes strain and blink less frequently, which can lead to insufficient lubrication of the eyes (i.e., dry eye).


There is a wide spectrum of treatments for dry eye, although without substantial efficacy for treatment of the condition. Treatment options include: artificial tear substitutes, ointments, gels, warm compresses, environmental modification, topical cyclosporine, omega-3 fatty acid supplements, punctal plugs, and moisture chamber goggles. Patients with severe disease may further be treated with punctal cautery, systemic cholinergic agonists, systemic anti-inflammatory agents, mucolytic agents, autologous serum tears, PROSE scleral contact lenses, and tarsorrhaphy. Despite these treatment options, dry eye continues to be considered one of the most poorly treated diseases in ophthalmology. Accordingly, it would be desirable to have a more effective treatment for dry eye.


BRIEF SUMMARY

Described here are devices, systems, and methods for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. Generally, the devices and systems may be configured to electrically stimulate the cornea and/or conjunctiva and/or subconjunctiva. In some variations, the devices may comprise a stimulator chip. An external power source may wirelessly transmit energy to the stimulator chip, where the stimulator chip may convert the energy transmitted to an electric waveform and electrically stimulate the cornea, conjunctiva and/or subconjunctiva. Stimulation may activate reflex pathways to increase tear production. The devices and systems for increasing tear production may be used in methods of treating dry eye, reducing the symptoms of tired eye, increasing comfort for contact lens wearers, and extending the number of years a contact lens user can wear contacts. Also described are methods of manufacturing a contact lens, where the contact lens is configured to increase tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva.


In some variations, the devices described here may comprise lens devices for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva of a subject. The devices may be in the form of a contact lens for placement on the cornea/conjunctiva of the eye. The contact lens may comprise a lens body and a stimulator chip, where the stimulator chip is within the lens body. Energy transmitted from the external power source to the stimulator chip may be converted to electrically stimulate the cornea, conjunctiva, and/or subconjunctiva. The lacrimal pathway may be initiated with activating sensory components in the cornea, conjunctiva, subconjunctiva, or surrounding orbital tissue. Stimulation may activate the lacrimal reflex to increase tear production.


In some variations, the devices described here may comprise implantable devices for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva of a subject. In some variations, the device may be in the form of an implantable device comprising a stimulator chip. The implantable device may utilize reflex pathways to activate the lacrimal gland, and in some cases the accessory glands, such as krause, zeiss, and meibomian glands, to increase tear production and tear quality. The implantable device may be placed subconjunctivally.


In some variations, the systems described here comprise systems for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva of a subject. In some variations, the system may comprise a device having a stimulator chip and an external power source. The external power source may be handheld or mountable for mounting to locations adjacent to where a patient may look for extended periods of time (e.g., a computer monitor, car windshield, television, etc.). The stimulator chip may receive wireless energy from the external power source and provide an electric stimulation waveform to the corneal and/or conjunctival innervation of the eye to increase tear production. In some variations, the external power source may be a laser diode or a light-emitting diode (LED), which may in some instances emit infrared (IR) light.


In some variations, the methods described here may comprise methods for increasing tear production in a subject. In some variations, the methods for increasing tear production may be used for treating DED caused by clinical factors, such as dysfunction of the lacrimal and/or meibomian glands. The treatment may also be for dry eye caused by external factors, such as medications, dehydration, and environmental pollutants. In some variations, the methods for increasing tear production may be for increasing comfort for contact lens wearers. In some variations, the methods for increasing tear production may be for reducing the symptoms of tired eye in patients not diagnosed as having DED. In some variations, the methods for increasing tear production may be for extending the number of years a contact lens user can wear contacts. The methods may comprise the step of stimulating the cornea, conjunctiva, and/or subconjunctiva to activate the reflex pathway and increase lacrimation.


In some variations, the methods described here comprise methods of manufacturing a contact lens configured to increase tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. The method of manufacturing a contact lens may comprise the step of embedding a stimulator chip in a lens body by sheet casting or rod casting. The method may further comprise the step of lathe cutting the casting to a desired shape. In some variations, the method of manufacturing a contact lens may comprise embedding a stimulator chip in a lens body and shaping the lens body by direct cast molding.


In some variations, the devices described here comprise a contact lens for increasing tear production in an eye of a subject. In some variations, the contact lens comprises a lens body configured for placement on a surface of the eye, and a stimulator chip configured to stimulate a cornea or a conjunctiva of the eye, where the stimulator chip is embedded within the lens body. In some variations, the lens body is a corrective lens. In some of these variations, the corrective lens is toric, aspheric, multifocal, diffractive, or scleral. In some variations, the lens body is non-corrective or non-refractive and has a zero power. In some variations, the lens body has a posterior surface configured to contact the conjunctiva of the eye, and the stimulator chip is embedded in the lens body within 20 microns of the posterior surface. In some variations, the stimulator chip is embedded in a portion of the lens body that is configured to cover an iris of the eye when the lens body is placed on the surface of the eye. In some variations, the stimulator chip is embedded in a portion of the lens body that is configured to be in front of an iris of the eye when the lens body is placed on the cornea of the eye. In some variations, the contact lens comprises a counterweight located approximately 180 degrees from the stimulator chip. In some of these variations, the counterweight is a second stimulator chip. In some variations, the contact lens comprises one or more weights for minimizing rotation of the contact lens. In some of these variations, the one or more weights is a second stimulator chip. In some variations, the stimulator chip is configured to receive energy wirelessly from an external power source and to convert the energy to a stimulation signal for electrically stimulating the cornea or the conjunctiva. In some of these variations, the stimulator chip comprises a power receiver configured to receive the energy wirelessly and to convert the energy to an electric signal. In some of these variations, the stimulator chip further comprises a signal conditioning unit configured to receive the electric signal and to modify the electric signal into an electric output. In some of these variations, modifying the electric signal comprises modifying one or more of a frequency, a shape, and an amplitude of the electric signal. In some variations, the stimulator chip further comprises electrode contacts configured to deliver the electric output to the cornea or the conjunctiva. In some of these variations, the electric output has a frequency that varies over time. In others of these variations, the electric output has a pulse width that varies over time. In some variations, the stimulator chip comprises a photodiode. In some variations, the stimulator chip comprises an integrated circuit. In some variations, the stimulator chip has a thickness between approximately 5 microns and 100 microns. In some of these variations, the thickness of the stimulator chip is approximately 20 microns.


In some variations, the systems described here are for increasing tear production in an eye of a subject. In some variations, the systems comprise a device configured for placement on a cornea, or in a subconjunctiva of the eye, where the device comprises a stimulator chip configured to stimulate the cornea or a conjunctiva of the eye, and an external power source for transmitting energy wirelessly to the stimulator chip to activate the stimulator chip. In some variations, the external power source is handheld. In other variations, the external power source is mountable. In some variations, the external power source comprises a laser diode. In some of these variations, the laser diode produces light comprising wavelengths between approximately 880 nm and 930 nm. In some variations, the external power source comprises an infrared light-emitting diode. In other variations, the external power source comprises an optical modifier to produce non-collimated light. In some of these variations, the optical modifier comprises a condenser lens and a microlens array. In some variations, the stimulator chip comprises a photodiode.


Also described here are methods of increasing tear production in a subject. In some variations, the methods comprise transmitting energy wirelessly from an external power source to a stimulator chip, where the stimulator chip is located in a subconjunctival space of an eye of the subject or is embedded in a contact lens worn by the subject, and delivering a stimulus from the stimulator chip to a conjunctiva or a cornea of the eye to produce tears. In some variations, the stimulator chip comprises a photodiode, and the external power source comprises a light source. In some of these variations, the light source comprises a laser diode. In other of these variations, the light source comprises an infrared light-emitting diode. In some variations, the method further comprises moving the eye to expose the photodiode to the light source. In some variations, the external power source is fixed to a location selected from the group consisting of a computer monitor, a car windshield, a television, and a forward face of a smart phone or a tablet. In some variations, the stimulator chip is within an implantable device located in the subconjunctival space of the eye. In some of these variations, the implantable device is secured in the subconjunctival space of the eye by one or more anchors. In some variations, the method further comprises periodically replacing the implantable device. In some of these variations, replacing the implantable device comprises removing the existing implantable device from a first location and placing a new implantable device in a second location. In some variations, the subject has dry eye, and the method of increasing tear production is used to treat the dry eye. In some variations, the subject is at an increased risk of developing dry eye, and the method of increasing tear production is used for prophylactic treatment of dry eye. In some variations, the subject has ocular allergies, and method of increasing tear production is used to treat the ocular allergies. In some variations, the subject wears contact lenses, and the method of increasing tear production is used for increasing comfort of wearing contact lenses. In some variations, the subject wears contact lenses, and the method of increasing tear production is used for extending a time period for which the subject can comfortably wear contact lenses. In some variations, the subject wears contact lenses, and the method of increasing tear production is used for extending a number of years for which the subject can wear contact lenses. In some variations, the subject has tired eye, and the method of increasing tear production is used for reducing symptoms of tired eye.


Also described here are methods for manufacturing a contact lens configured to treat dry eye. In some variations, the method comprises embedding a stimulator chip in a lens body, and shaping the lens body. In some variations, embedding comprises sheet casting. In other variations, embedding comprises rod casting. In some variations, shaping comprises lathe cutting. In some variations, the method comprises cast molding. In some variations, the contact lens has a posterior surface configured to contact a conjunctiva of an eye, and the stimulator chip is embedded in the lens body proximate to the posterior surface at a distance sufficient to allow for effective stimulation of a cornea and/or the conjunctiva of the eye by the stimulator chip.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a cut-away side view of an illustrative variation of a contact lens with a stimulator chip;



FIG. 2 shows a front view of an illustrative variation of a contact lens having a stimulator chip and a counterweight;



FIG. 3 shows an illustrative implantable device implanted in a position behind the lower eyelid;



FIG. 4 shows a block diagram illustrating a method of increasing tear production using a stimulator chip;



FIG. 5 shows an illustrative variation of a stimulator chip;



FIG. 6 shows an illustrative variation of the spectral response of a photodiode;



FIG. 7 shows an illustrative variation of an external power source comprising an optical modifier to produce non-collimated light;



FIG. 8 shows an illustrative variation of a system comprising a contact lens with a stimulator chip and a computer monitor-mounted external power source;



FIGS. 9A-9D show an illustrative variation of a method of manufacturing a contact lens using sheet casting;



FIGS. 10A-10D show an illustrative variation of a method of manufacturing a contact lens using rod casting;



FIGS. 11A-11C show an illustrative variation of the shaping of a contact lens from button form to a meniscus lens using lathe cutting;



FIGS. 12A-12D show an illustrative variation of a method of manufacturing a contact lens using cast molding.





DETAILED DESCRIPTION

Described here are devices, systems, and methods for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. The device may be a contact lens or an implantable device, which may comprise a stimulator chip. The system may comprise the contact lens or implantable device and an external power source that may wirelessly transmit energy to the stimulator chip. The stimulator chip may convert the energy transmitted to an electric waveform, which may be delivered to a subject to electrically stimulate the cornea, conjunctiva, and/or subconjunctiva. This may in turn activate the reflex pathways and increase tear production.


The devices and systems for increasing tear production described here may be used in methods of treating dry eye caused by clinical and/or external factors. They may also be used in methods of reducing the symptoms of tired eye, increasing comfort for contact lens wearers, and extending the number of years a contact lens user can wear contacts. Also described are methods of manufacturing a contact lens, where the contact lens is configured to increase tear production by stimulating the cornea and/or conjunctiva.


Devices


The devices described here may be for placement on the cornea or for placement in the subconjunctiva of the eye. The devices may comprise a stimulator chip for electrically stimulating the cornea and/or conjunctiva to increase lacrimation in patients suffering from dry eye, tired eye, and other conditions.


Contact Lens


As shown in FIG. 1, device 100 is in the form a contact lens 110 for placement on the cornea/conjunctiva of the eye. The contact lens 110 has a lens body 112 made from a biomaterial. The biomaterial can be any optically clear and biologically compatible material. Classifications of acceptable biomaterials include, but are not limited to: hydrophilic acrylates, hydrophobic acrylates, rigid poly(methyl methacrylate) (PMMA), and polyurethanes. Also acceptable are hydrogel materials, including but not limited to: silicone hydrogels, silicone acrylates (SAs), fluoro-silicone acrylates, and various gas-permeable materials. The biomaterial may be ionic or non-ionic, and may have a high water content or low water content, such as ranging from about 30% to about 70%. In some variations, the contact lens may have a monoblock lens body. In other variations, the contact lens may have a hybrid lens body comprising a soft, pliable, optically clear center portion and a rigid perimeter portion made from a rigid gas permeable material.


The contact lens may be corrective having a power specific to the patient's needs. The contact lens may also be a toric, aspheric, multifocal, diffractive, scleral, or other type of corrective contact lens. Alternatively, the lens may be non-corrective/refractive (i.e., zero power) for patients who do not require corrective lenses but suffer from dry eye, tired eye, or other eye conditions. The lens also may be a bandage contact lens for protecting and healing the eye and increasing comfort for patients with damaged or compromised corneas.


Contact lens 110 comprises a stimulator chip 114 within the lens body 112. Stimulator chip 114 may be configured to convert wireless energy transmitted from an outside source to an electric waveform for electrically stimulating the cornea/conjunctiva. Stimulator chip 114 is embedded in the lens body 112 and is positioned close to the posterior surface 116 adjacent to the eye. Close proximity of the stimulator chip to the eye surface may allow for effective stimulation of the cornea and/or conjunctiva. Accordingly, in some variations, the stimulator chip may be within 5 microns, within 10 microns, or within 10-20 microns of the posterior surface of the lens. Larger stimulators may be positioned further from the posterior surface. In other variations, the stimulator chip may be within 50-100 microns of the posterior surface. In other variations, such as with hybrid lens bodies described herein, the stimulator chip may be mounted directly to the surface of the lens body. The stimulator chip may be located in a number of positions in the lens body, but it may be desirable for the stimulator chip to be located in the portion of the lens body that covers the iris of the eye when inserted, so as to avoid blocking the visual axis.


In some instances it may be desirable that the contact lens be rotationally unstable to allow repositioning of the stimulator chip when blinking. This may reduce accommodation and habituation to the stimulus. In one variation, a single stimulator chip embedded in the lens body is light enough in weight to not unbalance the contact lens or prevent repositioning. In another variation, shown in FIG. 2, a counterweight 216 is located approximately 180 degrees from a first stimulator chip 214 in order to balance the weight and prevent the first stimulator chip 214 from weighing down and inhibiting rotation of contact lens 210. The counterweight 216 may be, for example, another stimulator chip, but may also be an inactive chip or any suitable object having appropriate weight and size.


However, in other instances such rotational instability may be undesirable. For example, contact lenses used for astigmatism are generally toric lenses having different optical power and focal length in two perpendicular orientations. In these cases, rotation of the lens may negatively affect vision, and therefore may not be desirable. In some variations for addressing astigmatism, one, two, or more inactive chips, or other weights, may be placed in the lower portion of the lens body in order to help the lens find a specific orientation and minimize rotation.


Implantable Device


In another variation, the device may be in the form of an implantable device. The implantable device may comprise a stimulator chip that is implanted within the eye and may utilize reflex pathways to provide activation to the lacrimal gland to increase tear production, and in some cases to provide activation of the accessory glands.


The implantable device may in some instances be placed subconjunctivally. The implantable device may be implanted in any location in the subconjunctiva where the stimulator chip can be exposed to energy transmission from an external power source. As shown in FIG. 3, it may be preferable for an implantable device 310 to be implanted in the subconjunctiva behind an eyelid (e.g., the lower eyelid) to avoid cosmetic impact. In this location, the implantable device 310 may be hidden when the subject looks straight ahead or side-to-side, but may become exposed when looking up. In other variations, the implantable device may be implanted such that it is visible when the subject looks straight ahead or side-to-side. In these cases, the implant may be configured with a decorative shape and/or distinct color (e.g., a red heart), so as to appear to be eye jewelry.


Because the conjunctiva defines an open space between it and the cornea, an implantable device inserted in the subconjunctival space may tend to migrate. Accordingly, the implantable device may comprise one or more fixation features to secure it in place. In some variations, fixation features may include one or multiple feet extending from the device. The feet may measure approximately 50-100 microns in length. In some instances, the feet may be pushed into the sclera for anchorage. Fixation features may also include an angled pick or nail for holding the device in place, biocompatible glue for initial fixation, or any other suitable anchoring feature.


The stimulator chip may have a coating of a thickness that allows the stimulation device to be atraumatic and non-irritating when implanted in the eye, but close enough to the conjunctiva to stimulate the nerves therein. Close proximity of the stimulator chip to the eye surface may allow for effective stimulation of the cornea, conjunctiva, and/or subconjunctiva, while exposure may result in a foreign body sensation and irritation. Accordingly, in some variations, the stimulator chip may have a coating that is between about 5 microns and about 20 microns thick. In some variations, a coating may comprise a hydrogel in order to allow for ionic conduction.


Stimulator Chip



FIG. 4 shows a block diagram illustrating how tear production may be increased using a stimulator chip as described herein. Generally, an external power 401 source may transmit wireless energy to a stimulator chip 406. The stimulator chip 406 may then convert the energy to a stimulation signal Eout comprising an electric waveform, which may be delivered to a subject for electrically stimulating the cornea/conjunctiva 408.


More specifically, the stimulator chip 406 may comprise a power receiver 403 and a signal conditioning unit 405. The power receiver 403 may be supplied with wireless energy from the external power source 401, and may convert the wireless energy to an electric signal Ein. The signal conditioning unit 405 may receive the electric signal Ein and then modify the electric signal Ein into the desired electric output Eout. The signal conditioning unit 405 may modify one or more of the signal's frequency, shape, and amplitude in any suitable manner (e.g., using resistive and capacitive elements, amplifiers). The electric output Eout may be a desired stimulation signal and may be delivered via electrode contacts to the cornea/conjunctiva 408 to activate lacrimation. While the variation of the system described with respect to FIG. 4 comprises a signal conditioning unit to modify the signal to the desired electrical stimulus, it should appreciated that in some variations, the signal may additionally or alternatively be manipulated using the external power source (e.g., by pulsing the power source in a particular pattern). With photovoltaics, for the example, manipulation of the signal may be done entirely externally by manipulation of the external power source.


In some variations, the stimulator chip may comprise one or more photodiodes, which act as both the power receiver and the signal conditioning unit. FIG. 5 shows a variation of a stimulator chip comprising an integrated circuit 500. The integrated circuit may be formed by semiconductor fabrication techniques on any suitable substrate, such as but not limited to a silicon on insulator (SOI) substrate. FIG. 5 shows an SOI semiconductor substrate 512 having an insulator layer 514. Light pulsed at a higher irradiance than ambient light, depicted by multiple arrows, is transmitted to the stimulator chip, which comprises a photodiode in region 510. The stimulation signal (i.e., the electric output) produced may be delivered through vias 516 to electrode contacts 518, 520 for stimulating the ocular tissue. A stimulator chip comprising a single photodiode, as in FIG. 5, may produce a voltage of up to about 0.6 V, but it should be appreciated that if higher voltage is desired, multiple diodes may be formed in series on the substrate. The stimulator chip may also comprise more than two electrodes in some variations.


The electrodes may each have dimensions (e.g., a diameter) measuring between 50 microns and 150 microns, specifically between 75 microns and 125 microns, or more specifically approximately 100 microns. This may result in an area of neural activation of approximately 100 microns. The electrodes may be made from any suitable material, such as but not limited to platinum or iridium oxide films. The stimulator chip may have a length measuring between 0.5 mm and 1.5 mm, specifically between 0.75 mm and 1.25 mm, or more specifically approximately 1.0 mm. The stimulator chip may have a width measuring between 0.5 mm and 1.5 mm, specifically between 0.75 mm and 1.25 mm, or more specifically approximately 1.0 mm. The stimulator chip may have a thickness measuring between 5 microns and 100 microns, specifically between 10 microns and 50 microns, or more specifically approximately 20 microns. In some variations, the stimulator chip measures 1.0 mm×1.0 mm×20 microns. The above-mentioned dimensions are exemplary only, and are not limited to the ranges provided. The stimulation chip and components thereof may be actually be larger, as their size may be limited only by the ability for the stimulator chip to fit within the contact lens and not block vision, while meeting the cosmetic requirements of the patient.


External Power Source


The external power source may be configured to wirelessly transmit energy to the stimulator chip. The external power source may comprise an on/off switch so it can be turned off when not in use by the patient. The external power source may be handheld or mountable for mounting to locations adjacent to where a patient may look for extended periods of time. Mounting locations include, but are not limited to, a computer monitor, car windshield, television, forward face of a smart phone, tablet, etc. In some variations, the mounting location may be on the frame of eyeglasses. A subject wearing a contact lens or having an implant as described herein may activate the stimulator chip by exposing a portion of the stimulator chip (e.g., a photodiode) to the power source. Moving the eye (e.g., looking up) may expose the stimulator chip to the energy transmitted by the power source.


In some variations in which the stimulator chip comprises a photodiode, the power source may comprise a light source, such as a laser diode. A laser diode may produce light within a relatively narrow wavelength band. This wavelength band may be chosen to be specific to the wavelength needed to excite the photodiode, while also avoiding wavelengths visible to humans. The responsivity curve of silicon-based photodiodes may end at approximately 1100 nm, while the human eye may be unable to see high intensity infrared light at wavelengths above approximately 850 nm. Therefore, it may be desirable to select a laser diode producing light comprising wavelengths in the range of approximately 880 nm to approximately 930 nm. FIG. 6 graphically shows the spectral response of an exemplary photodiode that could be used in the current application. In other variations, the external power source may comprise an infrared light-emitting diode (LED).


The desired wavelength range and power of the light transmitted by the power source may provide the energy required to cause the photodiode to generate current, without being phototoxic to the cornea and/or retina. To avoid harming the retina, it may be desirable for the intensity of the source to be below the levels known to cause damage to the retina, as specified in the American National Standard Institute (ANSI) Standards. In some variations, it may be desirable for the intensity of the source to be below the intensity of sunlight. If a photodiode in a stimulator chip as described herein has a surface area of 1 mm2, for example, pulsing the source at a 1% duty cycle may allow for a safe power range up to 100 mW. In some variations, the external power source described herein may emit 10 mW, pulsed at a 1% duty cycle, which is well within a safe range. The power that may be needed to be delivered to the photodiode may vary by device construction. In some variations, for example, the photodiode may require a power of approximately 0.1 mA to approximately 2 mA to generate a desired stimulation signal, and a light intensity of approximately 1 mW/mm2 to approximately 5 mW/mm2 may be needed to generate this. In some variations, the photodiode may require a power of approximately 1 mA to generate a desired stimulation signal, and a light intensity of approximately 3 mW/mm2 may be needed to generate this. However, it should be appreciated that the powers and light intensities desired may vary largely depending on implementation, and the power and intensity desired may increase for chips comprising more than one photodiode (e.g., may in some variations approximately double or triple for variations that utilize two or three diodes, respectively).


It may be desirable for the output of the external light source to be non-collimated. As shown in the diagram of FIG. 7, the external light source 702 may comprise an optical modifier 704 to produce non-collimated light 707. In some variations, the optical modifier 704 may comprise a condenser lens 705 and microlens array 706. The external light source 701 may also in some instances comprise a controller 703, which may modulate the output of the light source 702 to manipulate the desired output stimulus signal, in addition to or instead of a signal conditioning unit of a stimulator chip. In such variations, signal conditioning may be done almost entirely externally, and internal signal conditioning may only limit the voltage and/or current amplitude.


By manipulating the external power source, the electric signals delivered to the subject may be tailored for specific treatment regimens and/or specific subjects. The waveforms may be pulse-based or continuous. When the stimulator is configured to deliver a continuous waveform, the waveform may be a sinusoidal in amplitude and/or pulse-width, or quasi-sinusoidal, square-wave, sawtooth/ramped, or triangular waveform, truncated-versions thereof (e.g., where the waveform plateaus when a certain amplitude is reached), or the like.


In some variations, the stimulator may be configured to vary the frequency and/or pulse width of the waveform. This variation may occur according to a pre-determined plan, or may be configured to occur randomly within given parameters. For example, in some variations the continuous waveform may be configured such that the frequency or pulse width of the waveform varies over time (e.g., according to a sinusoidal function having a beat frequency). In some instances varying the frequency and/or pulse width of a stimulation waveform over time, or pulsing the stimulus on and off (e.g., 1 second on/1 second off, 5 seconds on/5 seconds off), may help reduce subject habituation (in which the subject response to the stimulation decreases during stimulation). Additionally or alternatively, ramping the amplitude of the stimulation waveform at the beginning of stimulation may increase comfort. Patterning may achieve a stronger reflex activation and thereby elicit more tearing in both eyes from stimulation in only one eye.


When the stimulator is configured to create a pulse-based electrical waveform, the pulses may be any suitable pulses (e.g., a square pulse, a haversine pulse, or the like). The pulses delivered by these waveforms may by biphasic, alternating monophasic, or monophasic, or the like. When a pulse is biphasic, the pulse may include a pair of single phase portions having opposite polarities (e.g., a first phase and a charge-balancing phase having an opposite polarity of the first phase). In some variations, it may be desirable to configure the biphasic pulse to be charge-balanced, so that the net charge delivered by the biphasic pulse is approximately zero. In some variations, a biphasic pulse may be symmetric, such that the first phase and the charge-balancing phase have the same pulse width and amplitude. In other variations, a biphasic pulse may be asymmetric, where the amplitude and/or pulse width of the first pulse may differ from that of the charge-balancing phase. Additionally, each phase of the biphasic pulse may be either voltage-controlled or current-controlled. In some variations, both the first phase and the charge-balancing phase of the biphasic pulse may be current-controlled. In other variations, both the first phase and the charge-balancing phase of the biphasic pulse may be voltage-controlled. In still other variations, the first phase of the biphasic pulse may be current-controlled, and the second phase of the biphasic pulse may be voltage-controlled, or vice-versa.


In variations where the waveform comprises a biphasic pulse, the biphasic pulse may have any suitable frequency, pulse widths, and amplitudes. For example, in instances where the stimulators described here are used to treat dry eye or otherwise produce a tearing response by stimulating the cornea and/or conjunctiva, the stimulator may be configured to generate a biphasic pulse waveform at a frequency between about 0.1 Hz and about 200 Hz. In some of these variations, the frequency is preferably between about 10 Hz and about 60 Hz. In some of these variations, the frequency is preferably between about 25 Hz and about 35 Hz. In others of these variations, the frequency is preferably between about 50 Hz and about 90 Hz. In some of these variations, the frequency is preferably between about 65 Hz and about 75 Hz. In other variations, the frequency is preferably between about 130 Hz and about 170 Hz. In some of these variations, the frequency is preferably between about 145 Hz and about 155 Hz. In some variations, high frequencies, such as those between about 145 Hz and about 155 Hz may be too high for each pulse to stimulate/activate the target nerves. As a result, the stimulation may be interpreted by the patient to have an element of randomness, which in turn may help to reduce subject habituation.


Similarly, when the stimulus is electrical and the first phase of the biphasic pulse is current-controlled, the first phase may preferably have an amplitude between about 10 μA and 20 mA. In some of these variations, the amplitude may be preferably between about 0.1 mA and about 10 mA. When the first phase of the biphasic pulse is voltage-controlled, the first phase may preferably have an amplitude between about 10 mV and about 25 V. Additionally, the first phase may preferably have a pulse width between about 1 μs and about 10 ms. In some of these variations, the pulse width may preferably be between about 10 μs and about 100 μs. In other variations, the pulse width may preferably be between about 100 μs and about 1 ms.


When an electrical pulse waveform is an alternating monophasic pulsed waveform, each pulse delivered by the stimulator may have a single phase, and successive pulses may have alternating polarities. Generally, the alternating monophasic pulses are delivered in pairs at a given frequency (such as one or more of the frequencies listed above, such as between 30 Hz and 50 Hz), and may have an inter-pulse interval between the first and second pulse of the pair (e.g., about 100 μs, between 50 μs and 150 μs or the like). Each pulse may be current-controlled or voltage-controlled, and consecutive pulses need not be both current-controlled or both voltage-controlled. In some variations where the pulse waveform is charged-balanced, the waveform may comprise a passive charge-balancing phase after delivery of a pair of monophasic pulses, which may allow the waveform to compensate for charge differences between the pulses.


As an alternative to optical coupling, power may be transferred to the stimulator chip from the external source using electromagnetic coupling or an electromagnetic telemetry link. For example, in some variations, the contact lens or implant may comprise an inductive coil and rectification circuit. In such variations, the external power source may be manipulated to control the frequency and pulse-width modulation of the stimulation signal.


Systems


A system as described herein may comprise a device having a stimulator chip and an external power source. The two components may be structurally and functionally configured to work together to increase tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. The external power source may deliver power and/or signal appropriate to activate the stimulator chip. FIG. 8 shows one variation of a system comprising a contact lens 810 with an embedded stimulator chip 814 as described herein, and a mountable external power source 850 mounted to a computer monitor 854. Transmission of wireless power 856 from the power source 850 to the stimulator chip 814 is illustratively shown. The distance x between the contact lens 810 and the mounted power source 850 is close enough for the stimulator chip 814 to receive the required intensity for the chip to generate the desired electrical stimulus.


Methods


The methods described here may comprise methods for treating dry eye and increasing tear production. Also described are methods for manufacturing a contact lens with an embedded stimulator chip.


Treatment Methods


The methods described here may comprise methods for treating dry eye and increasing tear production in a subject. The methods for increasing tear production may be used to treat a number of eye conditions and can provide immediate relief from discomfort and pain, as well as long-term improvements to overall ocular health. The treatment methods may involve one or more treatment regimens, such as providing stimulation to the cornea, conjunctiva, and/or subconjunctiva on an as-needed basis and/or according to a pre-determined regimen.


The method may be used to treat various forms of dry eye, including (but not limited to), chronic dry eye, episodic dry eye, seasonal dry eye, aqueous deficient dry eye, or evaporative dry eye. In some variations, the methods for increasing tear production may be used for treating DED caused by clinical factors, such as dysfunction of the lacrimal and/or meibomian glands. The treatment may also be for dry eye caused by external factors, such as medications, dehydration, and environmental pollutants. In some instances, the method may be used as a prophylactic measure to treat users who may be at an increased risk of developing dry eye, such as subjects who will undergo or who have undergone ocular surgery such as refractive vision correction and/or cataract surgery. In other instances, the method may be used to treat ocular allergies. For example, an increase in tear production may flush out allergens and other inflammatory mediators from the eyes.


In some variations, the methods for increasing tear production may be for increasing comfort for contact lens wearers. The system may be used in response to discomfort in order to decrease the discomfort associated with contact lens use. The system may also be used in response to discomfort to extend the time period for which an individual can comfortably wear contact lenses. Dryness and other conditions resulting from prolonged use of contact lenses may shorten the lifetime of contact lens use, which is often not past the age of forty. In some variations, the methods for increasing tear production may be for extending the number of years a contact lens user can wear contacts.


In some variations, the methods for increasing tear production may be for reducing the symptoms of tired eye in patients not diagnosed as having DED. Increased tear production may lead to more frequent blinking, which may in turn keep the eyes lubricated and reduce feelings of heaviness and strain.


Generally, the methods may comprise placing a device with a stimulator chip on the cornea or in the subconjunctiva of the eye of a subject. Because the nerves innervating the superior, inferior, and lateral portions of the conjunctiva (the supraorbital nerve, supratrochlear nerve, infratrochlear nerve, infraorbital nerve, and lacrimal nerve) go to the brain stem, stimulation of these nerves in only one eye may result in a bilateral tearing response. Accordingly, the step of placing a device on the cornea or in the subconjunctiva may involve placing the device in only one eye. For example, a subject may use a stimulating contact lens in one eye, and either no contact lens or a non-stimulating corrective contact lens in the other eye. In some variations, placement of the stimulating contact may be alternated between the eyes. In other variations, a subject may wear stimulating contact lenses in both eyes. Similarly, a stimulator chip may be implanted in only one eye to achieve a bilateral effect.


When the device comprises an implant configured to be implanted in the subconjunctival space, it may be implanted behind the lower eyelid, as described in more detail herein, where it can easily be periodically replaced (e.g., every six months) without any visible scarring. In some variations, an implantable device can be replaced by removing the old device and placing a new device in a position next to the previous position on the orbit (e.g., at the 5 o'clock position instead of the 6 o'clock position). This allows the former incision site to heal and recover. The next replacement of the implant may be put in yet another position near the old insertion site but still hidden behind the lower eyelid to avoid cosmetic impact. In some variations, the implantable device can be replaced by removing the old device and placing the new device in the opposite eye. This may reduce accommodation and/or minimize scarring.


In some instances, the eye may be imaged using high-resolution ultrasound, optical coherence tomography (OCT), or other imaging technique prior to implantation. The images may be used, for example, to assist in implanting the device (e.g., how deep to insert the implant based on the thickness of the conjunctiva or to verify that a patient is suitable for the procedure by possessing a conjunctiva that is thick enough to hold such an implanted device with a significant enough safety margin), selecting an appropriately sized/shaped implant for the patient's eye anatomy, and/or determining the source power needed to activate the stimulating chip.


After one or more contacts or implants is located on or in the eye, the methods may further comprise activating the stimulator chip using an external power source, and stimulating the cornea and/or conjunctiva to activate the reflex pathway and increase lacrimation and/or tear quality by increasing meibomian secretion or accessory gland secretion. In variations where the external power source is handheld, the handheld power source may be moved toward the eye, to a distance at which the external power source can deliver the intensity to generate the desired electrical stimulus. The distance can range from approximately 1 cm to approximately 1 m. Power sources at greater distances from the eye may require greater total power to activate the stimulator, due to light spread. In order to limit the total power output, and thus the potential for harming the iris, it may be desirable to have the distance be approximately 5-10 cm. In variations where the external power source is a mountable, the power source may have been mounted to a location adjacent to where the subject may look for extended periods of time, and the eye may be moved toward the external power source. When the external power source comprises an on/off switch, the power source may be turned on. If the stimulator chip is covered by an eyelid when the subject is looking forward, the eyeball (or, additionally or alternatively, the eyelid) may be moved to expose the stimulator chip to the power source.


Activation of the stimulator chip to generate a stimulus, which may in turn cause tearing or other effects, may be performed throughout the day on an as-needed basis and/or according to a pre-determined regimen. In some instances, a user may use one of the devices described herein to provide a round of stimulation when the user experiences symptoms of dry eye. A round of stimulation may have any suitable duration (e.g., between 1 second and 10 minutes). In other instances, the devices may be used to provide stimulation on a scheduled basis. For example, in some variations the devices described here may be used to provide a round of stimulation at least once daily, at least once weekly, or the like. In some variations, the devices may be used to deliver multiple rounds of stimulation each day (e.g., at least two treatments daily, at least four treatments daily, at least six times daily, between four and eight times daily, etc.) In some variations, the stimulation may be delivered at certain times of day. In other variations, the stimulation may be delivered at any time during the day as desired or determined by the user. When the device is used to provide stimulation on a scheduled basis, in some variations each round of stimulation may be the same length (e.g., about 30 seconds, about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes). In other variations, some rounds of stimulation may have different predetermined lengths. In yet other variations, the user may choose the length of the round of stimulation.


Methods of Manufacturing


In some variations, the methods described here comprise methods of manufacturing a contact lens that is configured to increase tear production by stimulating the cornea and/or conjunctiva. The manufacturing method is designed to reproducibly form a lens body with an embedded stimulator chip, where the stimulator chip is in a specific orientation and position within the lens body. Close proximity of the stimulator chip to the eye surface allows for effective stimulation of the cornea, conjunctiva, and/or subconjunctiva, while exposure of the stimulator chip to the eye may result in a foreign body sensation and irritation. Accordingly, in some variations, the stimulator chip may be within 5 microns, within 10 microns, or within 10-20 microns of the posterior surface of the lens.


Lathe Cutting


The methods of manufacturing a contact lens as described herein may comprise the step of embedding a stimulator chip in a lens body by sheet casting or rod casting. The method may further comprise the step of lathe cutting the casting to a desired shape.


When manufacturing the contact lens described here uses sheet casting, as shown in FIG. 9A, stimulator chips 918 may be set into a fixture 950. The stimulator chips 918 may be oriented with the electrodes 928, 930 positioned downwardly in the fixture 950 to create an electrode layer 952, as shown in FIG. 9B. A mix/pre-mix biomaterial may be poured into a mold 954 defined by the fixture 950. The biomaterial may be cured, post-cured, and annealed to create a biomaterial sheet 956, as shown in FIG. 9B. The electrode layer 952 may be sealed by reversing the biomaterial sheet 956, adding a thin film 958, and curing, as shown in FIG. 9C. Overall thickness of the sheet cast may be controlled by the curing time and temperature and thin-film thickness. FIG. 9D shows button development by milling, laser cutting, or coring of the sheets.


When manufacturing a contact lens described here uses rod casting, as shown in FIG. 10A, a rod mold 1050 may be developed. Stimulator chips 1018 may be fixated at pre-set levels/positions within the rod mold 1050. A pre-mix/monomer biomaterial may be poured into mold 1050. The biomaterial may be cured, post-cured, and annealed, as shown in FIG. 10B. FIG. 10C shows the steps of de-molding, and cutting or sawing the rod into buttons. A top view and side view of a button created from rod casting is shown in FIG. 10D.


Once the buttons are formed using sheet casting or rod casting methods, the biomaterial with embedded stimulator chips may be lathe cut to a meniscus shape. The anterior and posterior lathe cuts may be achieved by blocking the button on a chuck using vacuum or wax. The radius may be cut to various shapes and dimensions including aspheric surfaces, toric surfaces, multifocal, diffractive, and the like. Typical shapes for contact lenses are meniscus lenses. FIGS. 11A-11C show the shaping of a lens from button form to a meniscus lens using lathe cutting. FIG. 11A shows a side view of a button 1100 with a stimulator chip 1118. FIG. 11B shows the button of FIG. 11A with an anterior cut defining an anterior surface with three different radii of curvature R1, R2, and R3. FIG. 11C further shows a posterior cut defining an anterior surface with three different radii of curvature R4, R5, and R6.


Control over spacing of the stimulator chip and the posterior surface of the lens may be achieved by appropriately locating the stimulator chip on the button surface during casting stages. Thickness may be controlled using a combination of casting and lathing processes to ensure that the stimulator chip is close to the posterior surface of the contact lens without being exposed, as described in more detail herein.


Cast Molding


In some variations, the methods of manufacturing a contact lens may comprise embedding a stimulator chip in a lens body and shaping the lens body by direct cast molding. Disposable or metal molds that follow the contour/shape of the lens shown in FIG. 11C may be directly molded using highly polished surfaces (e.g., chrome- or steel-coated metal). As shown in FIG. 12A, a mold 1250 may comprise a first part 1252, a second part 1254, and a port 1256 for receiving a biomaterial. A stimulator chip 1218 may be positioned within the space 1258 created between first and second parts 1252, 1254 of mold 1250. A biomaterial, which may be a monomer mix, for example, may be fed into the space 1258. The biomaterial may be cured, cast, and de-molded to provide the intermediate lens 1260 shown in FIG. 12B.


To coat the second surface after cast molding, spray coating or thin-film coating may be employed. In some variations, as shown in FIG. 12C, a second mold 1262 may be used to create a thin layer to form the second surface. Lens 1260 may be placed in a space between a first part 1264 and a second part 1266 of mold 1262. A pre-mix biomaterial may be fed through a port 1268 and into the space, thereby creating a thin layer 1270 to a height of approximately 10-20 microns, or another suitable height as described herein. The biomaterial may be cured and de-molded. FIG. 12D shows a side view of the complete contact lens 1210 comprising the stimulator chip 1218 formed using cast molding method.


The final steps of processing may include hydration, cleaning, packaging, and sterilization or aseptic processing. An additional step of polishing, by tumble or pad for example, may be performed to achieve the surface quality desired.

Claims
  • 1. A method of increasing tear production in a subject, comprising: transmitting energy wirelessly from an external power source to a stimulator coupled to an implantable device body of an implantable device, wherein the implantable device is located in a subconjunctival space of an eye of the subject, and wherein the stimulator is configured to deliver a stimulus to a lacrimal nerve for increasing tear production, and wherein the stimulator comprises: a coating having a thickness that is configured to be atraumatic and non-irritating to the eye; anda photodiode for receiving the energy wirelessly and converting the energy to the stimulus; andstimulating a lacrimal nerve with the stimulus from the stimulator to cause an increase in tear production in the subject.
  • 2. The method of claim 1, wherein the external power source comprises a light source.
  • 3. The method of claim 2, wherein the light source comprises a laser diode.
  • 4. The method of claim 2, wherein the light source comprises an infrared light-emitting diode.
  • 5. The method of claim 2, further comprising moving the eye to expose the photodiode to the light source.
  • 6. The method of claim 1, wherein the method further comprises periodically replacing the implantable device by removing the implantable device from a first location and placing a new implantable device in a second location.
  • 7. The method of claim 1, wherein the implantable device includes one or more anchors configured to secure the implantable device in the subconjunctival space of the eye, the one or more anchors comprising one or more fixation features that are configured to be pushed into the sclera to secure the implantable device to the sclera.
  • 8. The method of claim 7, wherein the one or more fixation features comprises a length that is between approximately 50 microns and approximately 100 microns.
  • 9. The method of claim 7, wherein the one or more fixation features comprises one or more of an angled pick and a nail.
  • 10. A system for increasing tear production in an eye of a subject, the system comprising: a device configured for placement in a subconjunctiva of the eye, wherein the device comprises: an implantable device body; anda stimulator coupled to the implantable device body and configured to stimulate a conjunctiva of the eye, the stimulator configured to increase tear production in the eye of the subject by delivering an electrical stimulus to a lacrimal nerve of the subject, the stimulator comprising: a coating having a thickness that is configured to be atraumatic and non-irritating to the eye; anda photodiode for receiving energy wirelessly and converting the energy to the electrical stimulus; andan external power source for transmitting the energy wirelessly to the stimulator to activate the stimulator.
  • 11. The system of claim 10, wherein the external power source comprises a laser diode.
  • 12. The system of claim 11, wherein the laser diode produces light comprising wavelengths between approximately 880 nm and 930 nm.
  • 13. The system of claim 10, wherein the external power source comprises an optical modifier to produce non-collimated light.
  • 14. The system of claim 10, wherein the external power source comprises an infrared light-emitting diode.
  • 15. The system of claim 10, wherein the thickness of the coating is between approximately 5 microns and approximately 20 microns.
  • 16. The system of claim 10, wherein the coating comprises a hydrogel configured to allow for ionic conduction.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 14/920,847, filed Oct. 22, 2015, and titled “CONTACT LENS FOR INCREASING TEAR PRODUCTION,” which claims priority to U.S. Provisional Patent Application Ser. No. 62/067,395, filed on Oct. 22, 2014, and titled “CONTACT LENS FOR INCREASING TEAR PRODUCTION,” each of which is hereby incorporated by reference in its entirety.

US Referenced Citations (449)
Number Name Date Kind
2512882 Truesdale Jun 1950 A
2525381 Tower Oct 1950 A
3620219 Barker Nov 1971 A
3709228 Barker Jan 1973 A
3885550 MacLeod May 1975 A
D257495 Bros et al. Nov 1980 S
4495676 Hartmetz Jan 1985 A
4520825 Thompson et al. Jun 1985 A
4539988 Shirley et al. Sep 1985 A
4590942 Brenman et al. May 1986 A
4628933 Michelson Dec 1986 A
4681121 Kobal Jul 1987 A
4684362 Holt Aug 1987 A
4706680 Keusch et al. Nov 1987 A
4735207 Nambu et al. Apr 1988 A
4777954 Keusch et al. Oct 1988 A
4780932 Bowman et al. Nov 1988 A
4868154 Gilbard et al. Sep 1989 A
4926880 Claude et al. May 1990 A
4957480 Morenings Sep 1990 A
4988358 Eppley et al. Jan 1991 A
5025807 Zabara Jun 1991 A
5072724 Marcus Dec 1991 A
5078733 Eveleigh et al. Jan 1992 A
5090422 Dahl et al. Feb 1992 A
5099829 Wu Mar 1992 A
5147284 Fedorov et al. Sep 1992 A
5324316 Schulman et al. Jun 1994 A
5342410 Braverman Aug 1994 A
5345948 O'Donnell, Jr. Sep 1994 A
5352445 Lavaux Oct 1994 A
5360438 Fisher Nov 1994 A
5498681 Askari et al. Mar 1996 A
5514131 Edwards et al. May 1996 A
5533470 Rose Jul 1996 A
5545617 Dartt et al. Aug 1996 A
5571101 Ellman et al. Nov 1996 A
5607461 Lathrop Mar 1997 A
5611970 Apollonio et al. Mar 1997 A
5640978 Wong Jun 1997 A
5683436 Mendes et al. Nov 1997 A
5697957 Noren et al. Dec 1997 A
5707400 Terry et al. Jan 1998 A
5713833 Milligan Feb 1998 A
5720773 Lopez-Claros Feb 1998 A
5733282 Ellman et al. Mar 1998 A
5735817 Shantha Apr 1998 A
5792100 Shantha Aug 1998 A
5794614 Gruenke et al. Aug 1998 A
5800685 Perrault Sep 1998 A
5843140 Strojnik Dec 1998 A
5900407 Yerxa et al. May 1999 A
5904658 Niederauer et al. May 1999 A
5935155 Humayun et al. Aug 1999 A
5948006 Mann Sep 1999 A
6001088 Roberts et al. Dec 1999 A
6020445 Vanderlaan et al. Feb 2000 A
6035236 Jarding et al. Mar 2000 A
6050999 Paraschac et al. Apr 2000 A
6051017 Loeb et al. Apr 2000 A
6083251 Shindo Jul 2000 A
6102847 Stielau Aug 2000 A
6152916 Bige Nov 2000 A
6200626 Grobe, III et al. Mar 2001 B1
6205359 Boveja Mar 2001 B1
6208902 Boveja Mar 2001 B1
6240316 Richmond et al. May 2001 B1
6246911 Seligman Jun 2001 B1
6270796 Weinstein Aug 2001 B1
6272382 Faltys et al. Aug 2001 B1
6275737 Mann Aug 2001 B1
6277855 Yerxa Aug 2001 B1
6284765 Caffrey Sep 2001 B1
6324429 Shire et al. Nov 2001 B1
6327504 Dolgin et al. Dec 2001 B1
6366814 Boveja et al. Apr 2002 B1
6405079 Ansarinia Jun 2002 B1
6438398 Pflugfelder et al. Aug 2002 B1
6458157 Suaning Oct 2002 B1
6505077 Kast et al. Jan 2003 B1
6526318 Ansarinia Feb 2003 B1
6535766 Thompson et al. Mar 2003 B1
6537265 Thanavala et al. Mar 2003 B2
6539253 Thompson et al. Mar 2003 B2
6562036 Ellman et al. May 2003 B1
6564102 Boveja May 2003 B1
6578579 Burnside et al. Jun 2003 B2
6604528 Duncan Aug 2003 B1
6641799 Goldberg Nov 2003 B2
6658301 Loeb et al. Dec 2003 B2
6662052 Sarwal et al. Dec 2003 B1
6684879 Coffee et al. Feb 2004 B1
6701189 Fang et al. Mar 2004 B2
6748951 Schmidt Jun 2004 B1
6792314 Byers et al. Sep 2004 B2
6829508 Schulman et al. Dec 2004 B2
6853858 Shalev Feb 2005 B2
6871099 Whitehurst et al. Mar 2005 B1
6879859 Boveja Apr 2005 B1
6885888 Rezai Apr 2005 B2
6895279 Loeb et al. May 2005 B2
7024241 Bornzin et al. Apr 2006 B1
7054692 Whitehurst et al. May 2006 B1
7067307 Hochleitner et al. Jun 2006 B2
7069084 Yee Jun 2006 B2
7117033 Shalev et al. Oct 2006 B2
7142909 Greenberg et al. Nov 2006 B2
7146209 Gross et al. Dec 2006 B2
7169163 Becker Jan 2007 B2
7190998 Shalev et al. Mar 2007 B2
7225032 Schmeling et al. May 2007 B2
7228184 Heath Jun 2007 B2
7247692 Laredo Jul 2007 B2
7317947 Wahlstrand et al. Jan 2008 B2
7330762 Boveja et al. Feb 2008 B2
7346389 Newsome Mar 2008 B1
7346398 Gross et al. Mar 2008 B2
7369897 Boveja et al. May 2008 B2
7442191 Hovda et al. Oct 2008 B2
7460911 Cosendai et al. Dec 2008 B2
7477947 Pines et al. Jan 2009 B2
7502652 Gaunt et al. Mar 2009 B2
7547447 Yiu et al. Jun 2009 B2
7565204 Matei et al. Jul 2009 B2
7599737 Yomtov et al. Oct 2009 B2
7636597 Gross et al. Dec 2009 B2
7650186 Hastings et al. Jan 2010 B2
D613408 Gausmann et al. Apr 2010 S
D614303 Gausmann et al. Apr 2010 S
D614774 Gausmann et al. Apr 2010 S
7725176 Schuler et al. May 2010 B2
7725195 Lima et al. May 2010 B2
D617443 Grenon et al. Jun 2010 S
7758190 Korb et al. Jul 2010 B2
7778703 Gross et al. Aug 2010 B2
7778711 Ben-David et al. Aug 2010 B2
7792591 Rooney et al. Sep 2010 B2
7805200 Kast et al. Sep 2010 B2
7805202 Kuzma et al. Sep 2010 B2
7805203 Ben-David et al. Sep 2010 B2
7809442 Bolea et al. Oct 2010 B2
7835794 Greenberg et al. Nov 2010 B2
7846124 Becker Dec 2010 B2
7860570 Whitehurst et al. Dec 2010 B2
7873421 Karell Jan 2011 B2
7879079 Tu et al. Feb 2011 B2
D638128 Prokop et al. May 2011 S
7981095 Grenon et al. Jul 2011 B2
7993381 Mac et al. Aug 2011 B2
7998202 Lesh Aug 2011 B2
8002783 Vercellotti et al. Aug 2011 B2
8019419 Panescu et al. Sep 2011 B1
8019441 Wallace et al. Sep 2011 B2
8080047 Yu Dec 2011 B2
8083787 Korb et al. Dec 2011 B2
8145322 Yao et al. Mar 2012 B1
8155746 Maltan et al. Apr 2012 B2
8165680 Greenberg et al. Apr 2012 B2
8204591 Ben-David et al. Jun 2012 B2
8231218 Hong et al. Jul 2012 B2
8251983 Larson et al. Aug 2012 B2
8295529 Petersen et al. Oct 2012 B2
8318070 Shiah et al. Nov 2012 B2
D681839 Nathanson May 2013 S
8489189 Tronnes Jul 2013 B2
8494641 Boling et al. Jul 2013 B2
8521292 Wei et al. Aug 2013 B2
8626298 Simon Jan 2014 B2
8676324 Simon et al. Mar 2014 B2
8728136 Feldman May 2014 B2
8918181 Ackermann et al. Dec 2014 B2
8936594 Wolf et al. Jan 2015 B2
8986301 Wolf et al. Mar 2015 B2
8996137 Ackermann et al. Mar 2015 B2
9079042 Tiedtke et al. Jul 2015 B2
9095723 Ackermann et al. Aug 2015 B2
9265956 Ackermann et al. Feb 2016 B2
9440065 Ackermann et al. Sep 2016 B2
9687652 Franke et al. Jun 2017 B2
9717627 Kuzma et al. Aug 2017 B2
9737702 Ackermann et al. Aug 2017 B2
9737712 Franke et al. Aug 2017 B2
9764150 Loudin et al. Sep 2017 B2
9770583 Gupta et al. Sep 2017 B2
9821159 Ackermann et al. Nov 2017 B2
9956397 Loudin et al. May 2018 B2
D826420 Ackermann et al. Aug 2018 S
10143846 Ackermann et al. Dec 2018 B2
D837396 Ackermann et al. Jan 2019 S
10207108 Franke et al. Feb 2019 B2
20010018918 Burnside et al. Sep 2001 A1
20010020177 Gruzdowich et al. Sep 2001 A1
20020013594 Dinger et al. Jan 2002 A1
20020035358 Wang Mar 2002 A1
20020049290 Vanderbilt Apr 2002 A1
20020188331 Fang et al. Dec 2002 A1
20030014089 Chow Jan 2003 A1
20030045909 Gross et al. Mar 2003 A1
20030045911 Bruchmann et al. Mar 2003 A1
20030114899 Woods et al. Jun 2003 A1
20030120323 Meadows et al. Jun 2003 A1
20030130809 Cohen et al. Jul 2003 A1
20030139784 Morimoto et al. Jul 2003 A1
20030176898 Gross et al. Sep 2003 A1
20030192784 Zhou Oct 2003 A1
20030229381 Hochmair et al. Dec 2003 A1
20030233134 Greenberg et al. Dec 2003 A1
20030233135 Yee Dec 2003 A1
20040050392 Tu et al. Mar 2004 A1
20040059466 Block et al. Mar 2004 A1
20040098036 Bergersen May 2004 A1
20040098067 Ohta et al. May 2004 A1
20040127942 Yomtov et al. Jul 2004 A1
20040138646 Walla Jul 2004 A1
20040147973 Hauser et al. Jul 2004 A1
20040151930 Rouns et al. Aug 2004 A1
20040220644 Shalev et al. Nov 2004 A1
20050004621 Boveja et al. Jan 2005 A1
20050004625 Chow Jan 2005 A1
20050010250 Schuler et al. Jan 2005 A1
20050010266 Bogdanowicz Jan 2005 A1
20050101967 Weber May 2005 A1
20050101994 Yamazaki et al. May 2005 A1
20050105046 Tung May 2005 A1
20050137276 Yahiaoui et al. Jun 2005 A1
20050159790 Shalev Jul 2005 A1
20050197675 David et al. Sep 2005 A1
20050251061 Schuler et al. Nov 2005 A1
20050256570 Azar Nov 2005 A1
20050267542 David et al. Dec 2005 A1
20050268472 Bourilkov et al. Dec 2005 A1
20060004423 Boveja et al. Jan 2006 A1
20060018872 Tew et al. Jan 2006 A1
20060074450 Boveja et al. Apr 2006 A1
20060089673 Schultheiss et al. Apr 2006 A1
20060095077 Tronnes et al. May 2006 A1
20060095108 Chowdhury et al. May 2006 A1
20060100668 Ben-David et al. May 2006 A1
20060107958 Sleeper May 2006 A1
20060142822 Tulgar Jun 2006 A1
20060161225 Sormann et al. Jul 2006 A1
20060195169 Gross et al. Aug 2006 A1
20060206155 Ben-David et al. Sep 2006 A1
20060206162 Wahlstrand et al. Sep 2006 A1
20060216317 Reinhard et al. Sep 2006 A1
20060235430 Le et al. Oct 2006 A1
20060239482 Hatoum et al. Oct 2006 A1
20060259098 Erickson Nov 2006 A1
20060271024 Gertner et al. Nov 2006 A1
20060271108 Libbus et al. Nov 2006 A1
20060276738 Becker Dec 2006 A1
20070031341 DiMauro et al. Feb 2007 A1
20070038250 He et al. Feb 2007 A1
20070038267 Shodo et al. Feb 2007 A1
20070060815 Martin et al. Mar 2007 A1
20070060954 Cameron et al. Mar 2007 A1
20070083245 Lamensdorf et al. Apr 2007 A1
20070123938 Haller et al. May 2007 A1
20070135868 Shi et al. Jun 2007 A1
20070150034 Rooney et al. Jun 2007 A1
20070219600 Gertner et al. Sep 2007 A1
20070237797 Peyman Oct 2007 A1
20070237825 Levy et al. Oct 2007 A1
20070248930 Brawn Oct 2007 A1
20070250119 Tyler et al. Oct 2007 A1
20070250135 Bartz-Schmidt et al. Oct 2007 A1
20070255333 Giftakis et al. Nov 2007 A1
20070276314 Becker Nov 2007 A1
20070276451 Rigaux Nov 2007 A1
20070295327 Bottomley Dec 2007 A1
20070299420 Peyman Dec 2007 A1
20070299462 Becker Dec 2007 A1
20080009897 Duran Von Arx Jan 2008 A1
20080021515 Horsager et al. Jan 2008 A1
20080082057 Korb et al. Apr 2008 A1
20080082131 Llanos Apr 2008 A1
20080109054 Hastings et al. May 2008 A1
20080114424 Grenon et al. May 2008 A1
20080132933 Gerber Jun 2008 A1
20080140141 Ben-David et al. Jun 2008 A1
20080183242 Tano et al. Jul 2008 A1
20080183243 Shodo et al. Jul 2008 A1
20080208287 Palermo et al. Aug 2008 A1
20080208335 Blum Aug 2008 A1
20080221642 Humayun et al. Sep 2008 A1
20080269648 Bock Oct 2008 A1
20080288036 Greenberg et al. Nov 2008 A1
20080294066 Hetling et al. Nov 2008 A1
20090005835 Greenberg et al. Jan 2009 A1
20090012573 Karell Jan 2009 A1
20090018582 Ishikawa et al. Jan 2009 A1
20090024187 Erickson et al. Jan 2009 A1
20090024189 Lee et al. Jan 2009 A1
20090036945 Chancellor et al. Feb 2009 A1
20090043185 Mcadams et al. Feb 2009 A1
20090056709 Worsoff Mar 2009 A1
20090099600 Moore et al. Apr 2009 A1
20090099623 Bentwich Apr 2009 A1
20090099626 de Juan, Jr. et al. Apr 2009 A1
20090101139 Karell Apr 2009 A1
20090124965 Greenberg et al. May 2009 A1
20090138061 Stephens et al. May 2009 A1
20090156581 Dillon et al. Jun 2009 A1
20090157142 Cauller et al. Jun 2009 A1
20090157145 Cauller Jun 2009 A1
20090157147 Cauller et al. Jun 2009 A1
20090192571 Stett et al. Jul 2009 A1
20090192575 Carbunaru et al. Jul 2009 A1
20090204142 Becker Aug 2009 A1
20090239235 Demaria et al. Sep 2009 A1
20090241840 Mills Oct 2009 A1
20090264966 Blum et al. Oct 2009 A1
20090281594 King et al. Nov 2009 A1
20090281596 King et al. Nov 2009 A1
20090299418 Shalev et al. Dec 2009 A1
20090306738 Weiss et al. Dec 2009 A1
20090312818 Horsager et al. Dec 2009 A1
20100030150 Paques et al. Feb 2010 A1
20100076423 Muller Mar 2010 A1
20100087896 McCreery Apr 2010 A1
20100094280 Muller Apr 2010 A1
20100100165 Swanson et al. Apr 2010 A1
20100139002 Walker et al. Jun 2010 A1
20100152708 Li et al. Jun 2010 A1
20100161004 Najafi et al. Jun 2010 A1
20100168513 Pless et al. Jul 2010 A1
20100179468 Becker Jul 2010 A1
20100211132 Nimmagadda et al. Aug 2010 A1
20100241195 Meadows et al. Sep 2010 A1
20100274164 Juto Oct 2010 A1
20100274224 Jain et al. Oct 2010 A1
20100274313 Boling et al. Oct 2010 A1
20100280509 Muller et al. Nov 2010 A1
20100288275 Djupesland et al. Nov 2010 A1
20100311688 Chapin et al. Dec 2010 A1
20100318159 Aghassian et al. Dec 2010 A1
20110021975 Covello Jan 2011 A1
20110028807 Abreu Feb 2011 A1
20110028883 Juan, Jr. et al. Feb 2011 A1
20110076775 Stewart et al. Mar 2011 A1
20110077551 Videbaek Mar 2011 A1
20110077698 Tsampazis et al. Mar 2011 A1
20110081333 Shantha et al. Apr 2011 A1
20110082518 Filippello Apr 2011 A1
20110093043 Torgerson et al. Apr 2011 A1
20110151393 Frey et al. Jun 2011 A1
20110152969 Zehnder et al. Jun 2011 A1
20110184490 Horsager et al. Jul 2011 A1
20110202121 Wen Aug 2011 A1
20110218590 Degiorgio et al. Sep 2011 A1
20110234971 Yeh Sep 2011 A1
20110270067 Faraji Nov 2011 A1
20110270348 Goetz Nov 2011 A1
20110275734 Scales et al. Nov 2011 A1
20110276107 Simon et al. Nov 2011 A1
20110282251 Baker et al. Nov 2011 A1
20110295336 Sharma et al. Dec 2011 A1
20110313330 Loushin et al. Dec 2011 A1
20110313480 De Vos Dec 2011 A1
20110313481 De Vos Dec 2011 A1
20110313488 Hincapie Ordonez et al. Dec 2011 A1
20120053648 Neher et al. Mar 2012 A1
20120112903 Kaib et al. May 2012 A1
20120130398 Ackermann et al. May 2012 A1
20120133887 Huang May 2012 A1
20120197338 Su et al. Aug 2012 A1
20120232615 Barolat et al. Sep 2012 A1
20120232618 Feldman Sep 2012 A1
20120234332 Shantha Sep 2012 A1
20120253249 Wilson et al. Oct 2012 A1
20120298105 Osorio et al. Nov 2012 A1
20120315329 Ahn et al. Dec 2012 A1
20120316557 Sartor et al. Dec 2012 A1
20120323214 Shantha Dec 2012 A1
20120323227 Wolf et al. Dec 2012 A1
20120323232 Wolf et al. Dec 2012 A1
20120330376 Flynn et al. Dec 2012 A1
20130006095 Jenkins et al. Jan 2013 A1
20130006326 Ackermann Jan 2013 A1
20130053733 Korb et al. Feb 2013 A1
20130053737 Scerbo Feb 2013 A1
20130065765 Selifonov et al. Mar 2013 A1
20130158451 Juto et al. Jun 2013 A1
20130158626 Degiorgio et al. Jun 2013 A1
20130172790 Badawi Jul 2013 A1
20130178937 Vassallo et al. Jul 2013 A1
20130253387 Bonutti et al. Sep 2013 A1
20130261706 Mirro et al. Oct 2013 A1
20130270491 Park et al. Oct 2013 A1
20130274824 Otto et al. Oct 2013 A1
20130274831 Otto et al. Oct 2013 A1
20130304154 Goodman et al. Nov 2013 A1
20130310887 Curtis Nov 2013 A1
20130336557 Cruzat et al. Dec 2013 A1
20140012182 Shantha Jan 2014 A1
20140056815 Peyman Feb 2014 A1
20140081353 Cook et al. Mar 2014 A1
20140088463 Wolf et al. Mar 2014 A1
20140156000 Campin et al. Jun 2014 A1
20140163580 Tischendorf et al. Jun 2014 A1
20140214115 Greiner et al. Jul 2014 A1
20140214118 Greiner et al. Jul 2014 A1
20140214120 Simon et al. Jul 2014 A1
20140214124 Greiner et al. Jul 2014 A1
20140214125 Greiner et al. Jul 2014 A1
20140257205 Schaller Sep 2014 A1
20140257433 Ackermann et al. Sep 2014 A1
20140277429 Kuzma Sep 2014 A1
20140316310 Ackermann et al. Oct 2014 A1
20140316396 Wolf et al. Oct 2014 A1
20140316485 Ackermann et al. Oct 2014 A1
20140362339 Imafuku Dec 2014 A1
20140371565 Glasser Dec 2014 A1
20140371812 Ackermann et al. Dec 2014 A1
20150088156 Ackermann et al. Mar 2015 A1
20150238754 Loudin et al. Aug 2015 A1
20150335900 Ackermann et al. Nov 2015 A1
20150362755 Lee et al. Dec 2015 A1
20160022992 Franke et al. Jan 2016 A1
20160058615 Camras Mar 2016 A1
20160080720 Fullam Mar 2016 A1
20160114163 Franke et al. Apr 2016 A1
20160114172 Loudin et al. Apr 2016 A1
20160121118 Franke et al. May 2016 A1
20160158548 Ackermann et al. Jun 2016 A1
20160270656 Samec et al. Sep 2016 A1
20160367795 Ackermann et al. Dec 2016 A1
20160367806 Kahook Dec 2016 A1
20170049619 Kahook Feb 2017 A1
20170157401 Loudin et al. Jun 2017 A1
20170188947 Connor Jul 2017 A1
20170239459 Loudin et al. Aug 2017 A1
20170252563 Franke et al. Sep 2017 A1
20170312521 Franke et al. Nov 2017 A1
20170340884 Franke et al. Nov 2017 A1
20170354536 Kuzma et al. Dec 2017 A1
20170368332 Ackermann et al. Dec 2017 A1
20170368333 Loudin et al. Dec 2017 A1
20180064940 Ackermann et al. Mar 2018 A1
20180064941 Ackermann et al. Mar 2018 A1
20180064942 Franke et al. Mar 2018 A1
20180153394 Franke et al. Jun 2018 A1
20180154137 Ackermann et al. Jun 2018 A1
20180154161 Ackermann et al. Jun 2018 A1
20180161579 Franke et al. Jun 2018 A1
20180280688 Loudin et al. Oct 2018 A1
20190022392 Franke et al. Jan 2019 A1
20190167978 Ackermann et al. Jun 2019 A1
20190217095 Franke et al. Jul 2019 A1
Foreign Referenced Citations (112)
Number Date Country
1488331 Apr 2004 CN
101087822 Dec 2007 CN
101503491 Aug 2009 CN
101589085 Nov 2009 CN
101939043 Jan 2011 CN
102266592 Dec 2011 CN
103467652 Dec 2013 CN
102006048819 Apr 2008 DE
0109935 May 1984 EP
1 497 483 Jan 2005 EP
1 651 307 May 2006 EP
1 919 553 May 2008 EP
1 958 661 Aug 2008 EP
2 205 193 Jul 2010 EP
2 205 314 Jul 2010 EP
3263175 Jan 2018 EP
2129690 Mar 1987 GB
2456002 Jul 2009 GB
2102681-0001 Oct 2012 HK
2199000-0001 Mar 2013 HK
S60-500241 Feb 1985 JP
2002-519138 Jul 2002 JP
2002-325851 Nov 2002 JP
2002-539859 Nov 2002 JP
2004-508847 Mar 2004 JP
2004-526510 Sep 2004 JP
2005-502409 Jan 2005 JP
2005-052461 Mar 2005 JP
2005-144178 Jun 2005 JP
2005-521489 Jul 2005 JP
2005-528169 Sep 2005 JP
2006-515900 Jun 2006 JP
2006-311917 Nov 2006 JP
2007-044323 Feb 2007 JP
2007-528751 Oct 2007 JP
2008-55000 Mar 2008 JP
2008-183248 Aug 2008 JP
2008-541850 Nov 2008 JP
2009-506836 Feb 2009 JP
2009-523503 Jun 2009 JP
2010-505563 Feb 2010 JP
2010-051562 Mar 2010 JP
2010-506654 Mar 2010 JP
2010-537777 Dec 2010 JP
2011-030734 Feb 2011 JP
2011-524780 Sep 2011 JP
2012-100708 May 2012 JP
2012-115545 Jun 2012 JP
2012-200558 Oct 2012 JP
2013-528416 Jul 2013 JP
2338492 Nov 2008 RU
WO-0001320 Jan 2000 WO
WO-0056393 Sep 2000 WO
WO-0062672 Oct 2000 WO
WO-0185094 Nov 2001 WO
WO-02078592 Oct 2002 WO
WO-03023907 Mar 2003 WO
WO-03082080 Oct 2003 WO
WO-2003087433 Oct 2003 WO
WO-03101535 Dec 2003 WO
WO-2004026106 Apr 2004 WO
WO-2004026106 Apr 2004 WO
WO-2004043217 May 2004 WO
WO-2004043217 May 2004 WO
WO-2004091453 Oct 2004 WO
WO-2004112893 Dec 2004 WO
WO-2004112893 Dec 2004 WO
WO-2005007234 Jan 2005 WO
WO-2005007234 Jan 2005 WO
WO-2005030025 Apr 2005 WO
WO-2005030025 Apr 2005 WO
WO-2005060984 Jul 2005 WO
WO-2006127366 Nov 2006 WO
WO-2007028003 Mar 2007 WO
WO-2007079543 Jul 2007 WO
WO-2008048321 Apr 2008 WO
WO-2008156501 Dec 2008 WO
WO-2008156501 Dec 2008 WO
WO-2009035571 Mar 2009 WO
WO-2009035571 Mar 2009 WO
WO-2009048580 Apr 2009 WO
WO-2009070709 Jun 2009 WO
WO-2009154457 Dec 2009 WO
WO-2010003011 Jan 2010 WO
WO-2010027743 Mar 2010 WO
WO-2010069317 Jun 2010 WO
WO-2010099818 Sep 2010 WO
WO-2010123704 Oct 2010 WO
WO-2011011373 Jan 2011 WO
WO-2012068247 May 2012 WO
WO-2012139063 Oct 2012 WO
WO-2012139063 Oct 2012 WO
WO-2012155188 Nov 2012 WO
WO-2013055940 Apr 2013 WO
WO-2013055940 Apr 2013 WO
WO-2013157320 Oct 2013 WO
WO-2013162793 Oct 2013 WO
WO-2013165697 Nov 2013 WO
WO-2013166353 Nov 2013 WO
WO-2014138709 Sep 2014 WO
WO-2014165124 Oct 2014 WO
WO-2014172693 Oct 2014 WO
WO-2014172693 Oct 2014 WO
WO-2015130707 Sep 2015 WO
WO-2015130707 Sep 2015 WO
WO-2016015025 Jan 2016 WO
WO-2016025323 Feb 2016 WO
WO-2016065211 Apr 2016 WO
WO-2016065213 Apr 2016 WO
WO-2016065215 Apr 2016 WO
WO-2017192572 Nov 2017 WO
WO-2014153218 Sep 2019 WO
Non-Patent Literature Citations (99)
Entry
Olsen et al. “Human sclera: Thickness and surface area”. American Journal of Ophthalmology. Feb. 1998, vol. 125, Issue 2, pp. 237-241.
Boberg-Ans J. (1955). “Experience in clinical examination of corneal sensitivity: corneal sensitivity and the naso-lacrimal reflex after retrobulbar anaesthesia,” Br. J. Ophthalmol. 39(12):705-726.
Calonge (2001). “The Treatment of Dry Eye,” Survey Ophth. 45(2):S227-S239.
Corrected Notice of Allowance dated Jun. 9, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 2 pages.
Elsby et al. (1967). “Lacrimal Secretion in the Cat,” Br. J. Pharm. Chemother. 29(1):1-7.
Extended European Search Report received for European Patent Application No. 11842076.9, dated Oct. 10, 2014, 5 pages.
Extended European Search Report received for European Patent Application No. 12768458.7, dated Aug. 28, 2014, 7 pages.
Extended European Search Report dated Oct. 21, 2016, for EP Application No. 14 778 719.6, filed on Mar. 12, 2014, 8 pages.
Extended European Search Report dated Nov. 27, 2017, for EP Application No. 17 167 504.4, filed on Apr. 6, 2012, 9 pages.
Final Office Action for U.S. Appl. No. 13/441,806, dated Mar. 12, 2015, 10 pages.
Final Office Action for U.S. Appl. No. 13/441,806, dated May 20, 2016, 10 pages.
Final Office Action for U.S. Appl. No. 14/816,846, dated May 11, 2016, 12 pages.
Final Office Action received for U.S. Appl. No. 14/207,072, dated Jun. 22, 2016.
Final Office Action dated Sep. 23, 2016, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 10 pages.
Final Office Action dated Feb. 1, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 20 pages.
Final Office Action dated Mar. 10, 2017, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 12 pages.
Final Office Action dated May 17, 2017, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 5 pages.
Final Office Action dated Sep. 1, 2017, for U.S. Appl. No. 14/816,846, filed Aug. 3, 2015, 12 pages.
Final Office Action dated Dec. 20, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 18 pages.
International Search Report & Written Opinion received for PCT Patent Application No. PCT/US2011/060989, dated Feb. 23, 2012, 16 pages.
International Search Report & Written Opinion received for PCT Patent Application No. PCT/US2014/022158, dated Jul. 30, 2014, 8 pages.
International Search Report and Written Opinion received for PCT Application No. PCT/US2015/042130, dated Oct. 28, 2015.
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/057023, dated Mar. 4, 2016.
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/024496, dated Aug. 22, 2014, 11 pages.
International Search Report received for PCT Patent Application No. PCT/US2012/32629, dated Oct. 26, 2012, 4 pages.
International Search Report received for PCT Patent Application No. PCT/US2015/57021, dated Feb. 10, 2016, 4 pages.
International Search Report received for PCT Patent Application No. PCT/US2015/57019, dated Feb. 11, 2016, 4 pages.
Lora et al. (2009). “Lacrimal Nerve Stimulation by a Neurostimulator for Tear Production,” Invest. Ophth. Vis. Science 50(13):172.
Meng, I.D. et al. (2013). “The role of corneal afferent neurons in regulating tears under normal and dry eye conditions.” Exp. Eye Res. 117:79-87.
Non Final Office Action received for U.S. Appl. No. 13/441,806, dated Sep. 17, 2015, 11 pages.
Non-Final Office Action received for U.S. Appl. No. 13/298,042, dated Oct. 2, 2013, 10 pages.
Non-Final Office Action received for U.S. Appl. No. 13/441,806, dated Dec. 18, 2013, 9 pages.
Non-Final Office Action received for U.S. Appl. No. 14/201,753, dated Apr. 2, 2015, 6 pages.
Non-Final Office Action received for U.S. Appl. No. 14/809,109, dated Apr. 8, 2016, 8 pages.
Non-Final Office Action received for U.S. Appl. No. 14/816,846, dated Sep. 11, 2015, 5 pages.
Non-Final Office Action Received for U.S. Appl. No. 14/920,860, dated Aug. 17, 2016.
Non-Final Office Action Received for U.S. Appl. No. 14/920,852, dated Aug. 1, 2016.
Non Final Office Action received for U.S. Appl. No. 14/207,072, dated Dec. 9, 2015.
Non-Final Office Action dated Sep. 27, 2016, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 13 pages.
Non-Final Office Action dated Nov. 2, 2016, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 10pages.
Non-Final Office Action dated Dec. 6, 2016, for U.S. Appl. No. 14/816,846, filed Aug. 3, 2015, 13 pages.
Non-Final Office Action dated Jul. 17, 2017, for U.S. Appl. No. 15/598,063, filed May 17, 2017, 9 pages.
Non-Final Office Action dated Jul. 31, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 18 pages.
Notice of Allowance received for U.S. Appl. No. 14/201,753, dated Dec. 15, 2015, 2 pages.
Notice of Allowance received for U.S. Appl. No. 14/201,753, dated Oct. 15, 2015, 5 pages.
Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Apr. 29, 2014, 5 pages.
Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Aug. 11, 2014, 7 pages.
Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Nov. 13, 2014, 5 pages.
Notice of Allowance received for U.S. Appl. No. 14/561,107, dated Mar. 31, 2015, 7 pages.
Notice of Allowance dated Dec. 19, 2016, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 8 pages.
Notice of Allowance dated Jan. 19, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 5 pages.
Notice of Allowance dated Mar. 21, 2017, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 8 pages.
Notice of Allowance dated Mar. 28, 2017, for U.S. Appl. No. 14/207,072, filed Mar. 12, 2014, 8 pages.
Notice of Allowance dated Apr. 20, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 5 pages.
Notice of Allowance dated May 30, 2017, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 5 pages.
Notice of Allowance dated Aug. 2, 2017, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 5 pages.
Roessler et al. (2009). “Implantation and Explantation of a Wireless Epiretinal Retina Implant Device: Observations During the EPIRET3 Prospective Clinical Trial,” Invest. Ophthal. Visual Science 50(6):3003-3008.
Ruskell (2004). “Distribution of Pterygopalatine Ganglion Efferents to the Lacrimal Gland in Man,” Exp. Eye Res. 78(3):329-335.
Velikay-Parel et al. (2011). “Perceptual Threshold and Neuronal Excitability as Long-Term Safety Evaluation in Retinal Implants,” Invest. Opht. Visual Science E-Abstract 2590, 2 pages.
Written Opinion received for PCT Patent Application No. PCT/US2012/032629, dated Oct. 26, 2012, 8 pages.
Written Opinion received for PCT Patent Application No. PCT/US2015/57021, dated Feb. 10, 2016.
Written Opinion received for PCT Patent Application No. PCT/US2015/57019, dated Feb. 11, 2016, 6 pages.
“Vapor Pressure Data for H2O” (2012) Handbook of Chemistry and Physics, 73rd edition, 1 page.
Acar et al. (2013) “Ocular Surface Assessment in Patients with Obstructive Sleep Apnea—Hypopnea Syndrome”, Sleep Breath, 17(2):583-588. Published online: Jun. 5, 2012.
Amparo et al. (Jun. 2013) “Topical Interleukin 1 Receptor Antagonist for Treatment of Dry Eye Disease”, JAMA Ophthalmology, 131(6):715-723.
Anonymous (Apr. 2007) “The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye WorkShop”, The Ocular Surface, 5(2):93-107.
Bajpai et al. (Oct. 2012) “Preparation, Characterization and Water Uptake Behavior of Polysaccharide Based Nanoparticles”, Progresses in Nanotechnology and Nanomaterials, 1(1):9-17.
Baraniuk et al. (2007) “Nasonasal Reflexes, the Nasal Cycle, and Sneeze”, Current Allergy and Asthma Reports, 7:105-111.
Baroody et al. (Jun. 2009) “Fluticasone Furoate Nasal Spray Reduces the Nasal-Ocular Reflex: a Mechanism for the Efficacy of Topical Steroids in Controlling Allergic Eye Symptoms”, Journal of Allergy and Clinical Immunology, 123:1342-1348.
Baroody et al. (Mar. 2008) “Nasal Ocular Reflexes and Eye Symptoms in Patients with Allergic Rhinitis”, Annals of Allergy, Asthma & Immunology, 100:194-199.
Cipriano et al. (2014) “Superabsorbent Hydrogels that are Robust and Highly Stretchable”, American Chemical Society, 47(13):4445-4452.
Dart et al. (2002) “Effects of 25% Propylene Glycol Hydrogel (Solugel) on Second Intention Wound Healing in Horses”, Veterinary Surgery, 31(4):309-313.
Drummond (1995) “Lacrimation and Cutaneous Vasodilatation in the Face Induced by Painful Stimulation of the Nasal Ala and Upper Lip”, Journal of the Autonomic Nervous System, 51:109-116.
Eye Health (Feb. 10, 2014) “Watery Eyes in Cold Weather”, Oregon Eye Specialists, PC, located at http://www.oregoneyes.net/watery-eyes-in-cold-weather/, 3 pages.
Friedman (2010) “Impact of Dry Eye Disease and Impact on Quality of Life”, Current Opinion in Ophthalmology, 21:310-316.
Friedman et al. (2016) “A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease”, Clinical Ophthalmology, 10:795-804.
Fujisawa et al. (2002) “The Effect of Nasal Mucosal Stimulation on Schirmer Tests in Sjogren's Syndrome and Dry Eye”, Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3, Advances in Experimental Medicine and Biology, 506:1221-1226.
Galor et al. (Apr. 2014) “Environmental Factors Affect the Risk of Dry Eye Syndrome in a United States Veteran Population”, Ophthalmology, 121(4):972-973.
Gupta et al. (1997) “Nasolacrimal Stimulation of Aqueous Tear Production”, Cornea, 16(6):645-648.
Harvard Health Publishing (Nov. 2010) “Dry Eyes and What You Can Try”, Harvard Medical School, 2 pages.
Heigle et al. (1996) “Aqueous Tear Production in Patients with Neurotrophic Keratitis”, Cornea, 15(2):135-138.
Holzer (1991) “Capsaicin: Cellular Targets, Mechanisms of Action, and Selectivity for Thin Sensory Neurons”, Pharamalogical Reviews, 43(2):143-201.
Ikemura et al. (2008) “UV-VIS Spectra and Photoinitiation Behaviors of Acylphosphine Oxide and Bisacylphosphine Oxide Derivatives in unfilled, Light-Cured Dental Resins”, Dental Materials Journal, 27(6):765-774.
Krupin et al. (Jan. 1977) “Decreased Basal Tear Production Associated with General Anesthesia”, Archives of Ophthalmology, 95:107-108.
Loth et al. (1994) “Effect of Nasal Anaesthesia on Lacrimal Function After Nasal Allergen Challenge”, Clinical & Experimental Allergy, 24:375-376.
Mallepally et al. (2013) “Superabsorbent Alginate Aerogels”, The Journal of Supercritical Fluids, 79:1-5.
McDonald et al. (2009) “Hydroxypropyl Cellulose Ophthalmic Inserts (Lacrisert) Reduce the Signs and Symptoms of Dry Eye Syndrome and Improve Patient Quality of Life”, Transactions of the American Ophthalmological Society, 107:214-222.
Pasqui et al. (2012) “Polysaccharide-Based Hydrogels: The Key Role of Water in Affecting 98. Mechanical Properties”, Polymers, 4(3):1517-1534.
Petrov et al. (Jan. 2016) “SkQ1 Ophthalmic Solution for Dry Eye Treatment Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model”, Advances in Therapy, 33(1):96-115.
Philip et al. (Dec. 1994) “The Human Nasal Response to Capsaicin”, Journal of Allergy and Clinical Immunology, 94:1035-1045.
Sall et al. (Apr. 2000) “Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease”, Ophthalmology, 107(4):631-639.
Shaari et al. (Apr. 1995) “Rhinorrhea is Decreased in Dogs after Nasal Application of Botulinum Toxin”, Otolaryngology Head and Neck Surgery, 112(4):566-571.
Stjernschantz et al. (1979) “Electrical Stimulation of the Fifth Cranial Nerve in Rabbits: Effects on Ocular Blood Flow, Extravascular Albumin Content and Intraocular Pressure”, Experimental Eye Research, 28:229-238.
Stjernschantz et al. (1980) “Vasomotor Effects of Facial Nerve Stimulation: Noncholinergic Vasodilation in the Eye”, Acta Physiologica Scandinavica, 109:45-50.
Tsubota (1991) “The Importance of the Schirmer Test with Nasal Stimulation”, American Journal of Ophthalmology, 111(1):106-108.
Van Setten et al. (Aug. 2016) “Evidence of Seasonality and Effects of Psychrometry in Dry Eye Disease”, Acta Ophthalmologica, 94:499-506.
Yu, et al. (Apr. 2011) “The Economic Burden of Dry Eye Disease in the United States: a Decision Tree Analysis”, Cornea, 30(4):379-387.
Zilstorff-Pedersen (May 1965) “Quantitative Measurements of the Nasolacrimal Reflex”, Archives of Otolaryngology, 81:457-462.
Ahmed, E. M. et al. (2013, e-published Jul. 18, 2013). “Hydrogel: Preparation, characterization, and applications: A review,” Cairo University, Journal of Advanced Research (2015) 6, 105-121.
Related Publications (1)
Number Date Country
20170368359 A1 Dec 2017 US
Provisional Applications (1)
Number Date Country
62067395 Oct 2014 US
Divisions (1)
Number Date Country
Parent 14920847 Oct 2015 US
Child 15699905 US